How much revenue does Medy-Tox make?

Medy-Tox reported 247.29 billion KRW in revenue for fiscal year 2025, up 8.2% from 228.62 billion KRW in fiscal year 2024. In Q1 2026 revenue was 60.69 billion KRW.

Where does Medy-Tox make most of its revenue?

Foreign Country: 63% of revenue by region in fiscal year 2025, followed by South Korea (37%).

Medy-Tox Inc. (086900.KQ) Stock

About Medy-Tox Inc.

Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and C...

At a glance

Medy-Tox reported revenue of 247.29 billion KRW for fiscal year 2025, up 8.2% from fiscal year 2024, and net income of 16.59 billion KRW. In Q1 2026 (the quarter ended March 31, 2026) revenue was 60.69 billion KRW, down 5.1% from a year before. Foreign Country was its largest region in fiscal year 2025, with 63% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.